Revercom is a preclinical cancer therapy comprised of a liposome-packaged proprietary small molecule named Reversan. Reversan is a small molecule inhibitor of the multidrug transporter MRP1, which is associated with development of tumor resistance to chemotherapy.
Initial studies have demonstrated that Reversan sensitizes tumor cells to conventional chemotherapeutic drugs. Reversan is being developed as an adjuvant to conventional chemotherapy for use in potential treatment of a broad range of cancers (head and neck, bladder, melanoma, breast, prostate, and non-small cell lung carcinoma).
Our majority owned subsidiary, Panacela holds worldwide development and commercialization rights to Revercom.